

Cannabis Science Inc.
 Projected Share Values
 November 27, 2019

(Proposed NEW Trading IPO Common Shares A)

Common A Shares Authorized: 100,000,000 (\$25,000,000 Initial Raise)
 Common A Shares Issued: 0

(Proposed NEW Trading IPO Common Shares B)

Common B Shares Authorized: 5,000,000,000 (Capped, no more shares issued)
 Common B Shares Issued: 4,655,000,000 (Current Shareholders)

(Non-Trading)

Preferred Shares Authorized: 1,000,000
 Preferred Shares Issued: 1,000,000

Assumptions:

1. All shares retain the same dividend payout values.
2. All projected cash flows are consolidated to simplify the projected per share value.
3. All projects extrapolated are based on industry norms and general demographics.
4. All projected cash flows are based on approximated actuals and industry numbers
5. All projected FDA Drug cash flows are based on approved FDA Drugs.

Projected Cash flow Projects currently underway:

<u>FDA Target Drug</u>	<u>1% of Global Market</u>	<u>1% of USA Market</u>
Pancreatic Cancer	\$3,623,073,906.12	\$154,547,841.57
Stage 4 Lung Cancer	\$15,404,467,199.85	\$657,101,460.79
PTSD (CBN-Patent)	\$86,441,834,422.22	\$3,687,310,631.07
Sleep Deprivation (CBN Patent)	\$5,400,203,846.10	\$230,354,077.80

***We have several more targets not listed, but underway, they will multiply our outcomes.

Projected share values:

(4 Drugs), 1% of the USA Market: \$ 4,729,314,011.23

Total shares: Common Class A & B = 5,100,000,000 / Projected Revenues / 25% Net Profit

Per share value: Assume (\$1.00 per share revenues) / (\$0.25 per share, net profit)

Share Price: Assume trading is typical @ 50-100 times earnings per share = \$1.00 - \$25.00 per share

Partnerships will split the revenues and earnings per shares and reflect the share trading price accordingly